<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982553</url>
  </required_header>
  <id_info>
    <org_study_id>2009-010005-36</org_study_id>
    <secondary_id>2009-010005-36</secondary_id>
    <nct_id>NCT00982553</nct_id>
  </id_info>
  <brief_title>The Raltegravir and Ribavirin Pharmacokinetics (PK) Study</brief_title>
  <official_title>A Prospective, Open-label, Three Phase Pharmacokinetic Study, to Assess the Pharmacokinetic Profile and Safety of Raltegravir 400 mg Twice Daily and Ribavirin 800 mg Once Daily, When Dosed Separately and Together in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at levels of both a new anti-HIV drug called raltegravir
      and an existing anti-hepatitis C drug called ribavirin to see if they affect the blood levels
      of each other when given separately and together. This is a phase I, open-label, prospective,
      three phase, pharmacokinetic study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I (study day 1 - 14):

        -  14 healthy volunteers with a documented negative HIV-1 antibody test during screening
           procedures will be enrolled.

        -  On day 1, fasted subjects will be administered ribavirin 800 mg without food (witnessed
           dosing). This will be followed be a 12 hour detailed pharmacokinetic assessment; blood
           sampling drawn at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 and 12 hours.

        -  This will be followed by a wash-out period.

        -  As steady state pharmacokinetics of ribavirin are not reached for several weeks, single
           dosing pharmacokinetics will be assessed in this study

      Phase II (study days 15 - 19):

        -  On day 15, subjects will commence raltegravir 400 mg twice daily. Subjects will attend
           for safety visits and witnessed dosing during this phase.

        -  Day 19 - after 4 days of dosing when steady state pharmacokinetics has been reached,
           subjects will attend for a 12 hour detailed pharmacokinetic visit where following
           witnessed administration of raltegravir 400 mg without food, blood sampling will be
           drawn at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post dose for the assessment
           of raltegravir plasma exposure.

      Phase III (study day 20):

      â€¢ Subjects will be administered raltegravir 400 mg and ribavirin 800 mg without food. This
      will be followed by a 12 hour detailed pharmacokinetic assessment with blood sampling drawn
      at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 12 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ribavirin Maximum Plasma Concentration</measure>
    <time_frame>Day 20</time_frame>
    <description>Pharmacokinetic analyses of blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Raltegravir Maximum Plasma Concentration</measure>
    <time_frame>Day 20</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ribavirin Minimum Plasma Concentration</measure>
    <time_frame>Day 20</time_frame>
    <description>Ribavirin minimum plasma concentration by pharmacokinetic analyses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Raltegravir Minimum Plasma Concentrations</measure>
    <time_frame>Day 20</time_frame>
    <description>Raltegravir minimum plasma concentrations by pharmacokinetic analyses</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Phase 1_ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Single dose ribavirin (800 mg) administered on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2_raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Raltegravir (400 mg twice daily) administered from days 15-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase3_ribavirin+raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Ribavirin (800 mg) and Raltegravir (400 mg) administered day 20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>800mg once daily</description>
    <arm_group_label>Phase 1_ribavirin</arm_group_label>
    <arm_group_label>Phase3_ribavirin+raltegravir</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400mg twice daily</description>
    <arm_group_label>Phase2_raltegravir</arm_group_label>
    <arm_group_label>Phase3_ribavirin+raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The ability to understand and sign a written informed consent form, prior to
             participation in any screening procedures and must be willing to comply with all study
             requirements.

          -  Male or non-pregnant, non-lactating female.

          -  Between 18 to 60 years, inclusive.

          -  Subjects in good health upon medical history, physical exam, and laboratory testing
             and body mass index below 32.

          -  Female subjects who are heterosexually active and of childbearing potential (i.e., not
             surgically sterile or at least two years post menopausal) must practice contraception
             as follows from screening through completion of the study including 180 days following
             last dose of study drug:

               -  barrier contraceptives (condom, diaphragm with spermicide)

               -  oral combined contraceptive pill, implant or injectable hormonal contraceptive
                  PLUS a barrier contraceptive

               -  Intrauterine device (IUD) or intrauterine system (IUS) PLUS a barrier
                  contraceptive (or a partner who has been vasectomized for at least six months).

          -  Female subjects of childbearing potential must have a negative urine pregnancy test.

          -  Male subjects who are heterosexually active must use two forms of barrier
             contraception (e.g., condom with spermicide) during heterosexual intercourse, from
             screening through completion of the study including 180 days following last dose of
             study drug.

          -  Have no serologic evidence of HIV infection.

          -  Have no serologic evidence of active hepatitis B virus infection evidenced by negative
             hepatitis B surface antigen and no serologic evidence of hepatitis C virus infection
             through antibody testing.

          -  Have screening laboratory results (haematology, chemistry) that fall within the normal
             range of the central laboratory's reference ranges unless the results have been
             determined by the Investigator to have no clinical significance.

        Exclusion Criteria:

          -  Any serious or active medical or psychiatric illness which, in the opinion of the
             Investigator, would interfere with subject treatment, assessment, or compliance with
             the protocol. This would include any active clinically significant renal, cardiac,
             hepatic, pulmonary, vascular, metabolic (thyroid disorders, adrenal disease),
             immunodeficiency disorders, active infection, or malignancy.

          -  Have a body mass index (BMI) greater than 32

          -  Previous participation in an investigational trial involving administration of any
             investigational compound within 1 month prior to the study screening.

          -  Clinically relevant alcohol or drug use (positive screening drug screen) or history of
             alcohol or drug use considered by the Investigator to be sufficient to hinder
             compliance with treatment, follow-up procedures or evaluation of adverse events.
             Smoking is permitted, but tobacco intake should remain consistent throughout the
             study.

          -  Any medication taken listed in Prior and Concomitant Medication section including
             over-the-counter medications and herbal products within 21 days of commencing study
             drug dosing with the exception of vitamins and/or paracetamol and/or hormonal
             contraceptives including the combined oral contraceptive pill, Depo-Provera and the
             Mirena intrauterine system. When a concomitant medication is necessary, this will be
             reviewed by the Investigator and if not contraindicated, may be continued at the same
             dose and frequency during the study period.

          -  History of drug sensitivity or drug allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Winston, MB BH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ashby J, Garvey L, Erlwein OW, Lamba H, Weston R, Legg K, Latch N, McClure MO, Dickinson L, D'Avolio A, Back D, Winston A. Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. J Antimicrob Chemother. 2011 Jun;66(6):1340-5. doi: 10.1093/jac/dkr093. Epub 2011 Mar 15.</citation>
    <PMID>21406434</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <results_first_submitted>February 28, 2011</results_first_submitted>
  <results_first_submitted_qc>May 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2011</results_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was between 24/09/2009 and 29/10/2009.
14 subjects were enrolled.
The study took place at a specialist research unit at an National Health Service (NHS) hospital.</recruitment_details>
      <pre_assignment_details>Subjects were healthy volunteers.
There was a 21 day washout for any prescribed and 7 days for over the counter medication before enrolment.
The subjects were permitted to take paracetamol during the study but all others were excluded for the duration of the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>All subjects received the same study therapy as follows:
Day 1 Ribavirin single dose 800 mg oral followed by intensive PK monitoring. Day 2 - 14 washout phase Day 15 - 18 raltegravir 400 mg twice daily followed by by intensive PK monitoring on day 18.
Day 19 raltegravir 400 mg plus ribavirin 800 mg by intensive PK monitoring.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects received the same study therapy as follows:
Day 1 Ribavirin single dose 800 mg oral followed by intensive PK monitoring. Day 2 - 14 washout phase Day 15 - 18 raltegravir 400 mg twice daily followed by by intensive PK monitoring on day 18.
Day 19 raltegravir 400 mg plus ribavirin 800 mg by intensive PK monitoring.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ribavirin Maximum Plasma Concentration</title>
        <description>Pharmacokinetic analyses of blood samples</description>
        <time_frame>Day 20</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Phase1_ribavirin</title>
            <description>Single dose ribavirin 800mg administered on day 1</description>
          </group>
          <group group_id="O2">
            <title>Phase3_ribovarin and Raltegravir</title>
            <description>Single dose ribavirin 800mg and raltegravir 400mg at day 20</description>
          </group>
        </group_list>
        <measure>
          <title>Ribavirin Maximum Plasma Concentration</title>
          <description>Pharmacokinetic analyses of blood samples</description>
          <population>Per protocol</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630.09" lower_limit="490.91" upper_limit="808.54"/>
                    <measurement group_id="O2" value="496.71" lower_limit="407.38" upper_limit="605.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric mean ratios</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Raltegravir Maximum Plasma Concentration</title>
        <time_frame>Day 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase2_Raltegravir</title>
            <description>Raltegravir 400 mg twice daily on day 15-19</description>
          </group>
          <group group_id="O2">
            <title>Phase3_ribovarin and Raltegravir</title>
            <description>On day 20 single dose of both ribavirin and raltegravir administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Raltegravir Maximum Plasma Concentration</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2227.41" lower_limit="1489.36" upper_limit="3331.19"/>
                    <measurement group_id="O2" value="2591.19" lower_limit="1778.28" upper_limit="3774.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric mean ratios</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ribavirin Minimum Plasma Concentration</title>
        <description>Ribavirin minimum plasma concentration by pharmacokinetic analyses</description>
        <time_frame>Day 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase1_Ribavirin</title>
            <description>Single dose ribavirin 800mg administered on day 1</description>
          </group>
          <group group_id="O2">
            <title>Phase3_ribovarin and Raltegravir</title>
            <description>Onn day 20 single dose of both ribavirin and raltegravir administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Ribavirin Minimum Plasma Concentration</title>
          <description>Ribavirin minimum plasma concentration by pharmacokinetic analyses</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.71" lower_limit="148.59" upper_limit="229.61"/>
                    <measurement group_id="O2" value="186.98" lower_limit="157.83" upper_limit="221.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric mean ratios</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Raltegravir Minimum Plasma Concentrations</title>
        <description>Raltegravir minimum plasma concentrations by pharmacokinetic analyses</description>
        <time_frame>Day 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase2_Raltegravir</title>
            <description>Raltegravir 400 mg twice daily on day 15-19</description>
          </group>
          <group group_id="O2">
            <title>Phase3_ribovarin and Raltegravir</title>
            <description>On day 20 single dose of both ribavirin and raltegravir administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Raltegravir Minimum Plasma Concentrations</title>
          <description>Raltegravir minimum plasma concentrations by pharmacokinetic analyses</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.97" lower_limit="45.64" upper_limit="154.45"/>
                    <measurement group_id="O2" value="68.91" lower_limit="40.74" upper_limit="116.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric mean ratios</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>All subjects received the same study therapy as follows:
Day 1 Ribavirin single dose 800 mg oral followed by intensive PK monitoring. Day 2 - 14 washout phase Day 15 - 18 raltegravir 400 mg twice daily followed by by intensive PK monitoring on day 18.
Day 19 raltegravir 400 mg plus ribavirin 800 mg by intensive PK monitoring.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Alan Winston</name_or_title>
      <organization>Imperial College</organization>
      <phone>+44 (0)20 3312 1603</phone>
      <email>a.winston@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

